Abstract:Nomogram has demonstrated its capability in individualized survival estimates. Some nomogram studies on esophageal squamous cell carcinoma (ESCC) have been reported, but accuracy of those nomograms is not high enough. Also, the role of ESCC nomogram in adjuvant chemotherapy remains unclear. Therefore, clinicopathological prognostic nomogram was developed and validated for patients with ESCC in this study. Its role in personalized adjuvant chemotherapy was investigated as well. Data were retrieved about 1042 ESCC patients undergoing right transthoracic radical esophageactomy at Sun Yat-sen University Cancer Center from January 1997 to December 2013. Of 1042 patients, 886 without adjuvant chemotherapy were divided into training set (Group A, n=590) and validation set (Group B, n=296) in a 2:1 ratio. Group C (the remaining 156 patients with adjuvant chemotherapy plus Group B, n=452) was used to evaluate the role of nomogram in personalized adjuvant chemotherapy. Cut-off points of continuous variables were established by X-tile. Survival and univariate analyses were calculated by Kaplan–Meier method. R software and “rms” package were used to perform Cox proportional hazard (CPH) regression model, plot nomogram, compute C-index, compare models, validate model, and plot calibration curve. The “survivalROC” package was used to plot time-dependent receiver operating curve (ROC). The 1-, 3- and 5-year overall survival (OS) for the entire cohort was 88.3%, 64.5% and 54.8%, respectively. Univariate analyses were performed for 13 potential clinicopathological factors. Significant variables were analyzed for CPH regression model using R software and “rms” package. A prognostic nomogram including 8 factors (grade, location, T, N, resected negative nodes, length, gender, drinking history) was developed. C-index of the model was 0.739 (95% CI 0.719-0.759), higher than that of the 7th TNM staging system (0.696, 95% CI 0.676-0.716), p <0.001. The calibration curve and time-dependent ROC showed this nomogram was superior to the 7th TNM staging system. The cut-off of prognostic score was 160, by which we grouped patients into low and high prognostic risk subgroup. In Group C, 209 patients belonged to high prognostic risk subgroup. Among them, patients receiving adjuvant chemotherapy had longer OS (p = 0.035). The remaining 243 patients belonged to low prognostic risk subgroup. Adjuvant chemotherapy didn’t improve OS (p = 0.799) in this subgroup. An accuracy clinicopathological prognostic nomogram was developed and validated for ESCC patients undergoing right transthoracic radical esophagectomy. The nomogram provided individual prediction of survival. Risk group stratification based on nomogram prognostic score successfully guided personalized adjuvant chemotherapy for ESCC patients.

Survival risk stratification based on prognosis nomogram to identify patients with esophageal squamous cell carcinoma who may benefit from postoperative adjuvant therapy

A neotype nomogram based on accessible clinical indicators to predict the overall survival of esophageal cancer patients underwent radical resection

The Development of a Nomogram and the Prognostic Prediction Value of Patients with Esophageal Squamous Cell Carcinoma Undergoing Radical Radiotherapy.

A Prognostic Nomogram for Overall Survival after Neoadjuvant Radiotherapy or Chemoradiotherapy in Thoracic Esophageal Squamous Cell Carcinoma: a Retrospective Analysis

Development of a prognostic nomogram for esophageal squamous cell carcinoma patients received radiotherapy based on clinical risk factors

A national multicenter retrospective clinical study to develop a prognostic nomogram for patients with esophageal squamous cell carcinoma based on definitive radiotherapy (3JECROG R-03A)

Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy

OA 03.07 Developing Prognostic Nomogram and Evaluating Its Role in Personalized Adjuvant Chemotherapy for Patients with ESCC

Nomogram-Based Survival Predictions and Treatment Recommendations for Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Upfront Surgery

Development of a prognostic nomogram and risk stratification system for upper thoracic esophageal squamous cell carcinoma

Clinical Nomogram for Predicting Survival of Esophageal Cancer Patients after Esophagectomy

Analysis of prognostic factors and nomogram for predicting survival for patients with locally resectable esophageal cancer after preoperative chemoradiation therapy

Prognostic Nomogram for Previously Untreated Patients with Esophageal Squamous Cell Carcinoma after Esophagectomy Followed by Adjuvant Chemotherapy

A Reliable Nomogram is Identified to Predict the Overall Survival for Patients with Esophageal Squamous Cancer after Chemoradiation Therapy Followed by Surgery

Nomogram constructed by immunological and inflammatory indicators for predicting prognosis of patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy plus surgery

A Nomogram Model to Predict Post-Progression Survival in Esophageal Squamous Cell Carcinoma Patients with Recurrence after Radical Resection

Prognostic Nomogram for Predicting Long-Term Overall Survival of Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Plus Surgery: A Population-Based Study

Development and validation of a novel prognostic model for patients with surgically resected esophageal squamous cell carcinoma

Prognostic prediction model for patients with pathological T1N0 stage esophageal squamous cell carcinoma undergone esophagectomy

Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery